Yaxiong Z. Zhang

State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

Efficacy comparisons of chemotherapy regimens with different intensities in high-risk pediatric hepatoblastoma

Efficacy comparisons of chemotherapy regimens with different intensities in high-risk pediatric hepatoblastoma

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: August 13, 2026

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.

Journal: JAMA oncology

Published: January 29, 2026

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 23, 2025

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.

Journal: Cell communication and signaling : CCS

Published: October 14, 2025

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.

Journal: The oncologist

Published: August 07, 2025

Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.

Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.

Journal: Cancer cell

Published: August 01, 2025

Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis.

Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis.

Journal: Translational lung cancer research

Published: April 27, 2025

First case report of immune checkpoint inhibitor-related pneumonitis triggered by bispecific antibody (anti-PD-L1 and anti-CTLA-4) in a patient with non-small cell lung cancer: case report.

First case report of immune checkpoint inhibitor-related pneumonitis triggered by bispecific antibody (anti-PD-L1 and anti-CTLA-4) in a patient with non-small cell lung cancer: case report.

Journal: Translational lung cancer research

Published: April 22, 2025

Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.

Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.

Journal: BMC cancer

Published: March 31, 2025

Activating NEDD4L suppresses EGFR-driven lung adenocarcinoma growth via facilitating EGFR proteasomal degradation.

Activating NEDD4L suppresses EGFR-driven lung adenocarcinoma growth via facilitating EGFR proteasomal degradation.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 23, 2025

Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study.

Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study.

Journal: iScience

Published: March 18, 2025

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study.

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study.

Journal: Journal of hematology & oncology

Published: March 11, 2025

Showing 1-12 of 98

Last Updated: 09/26/2026